MAP2K7 and acute myeloid leukemia: MEK/ERK inhibition enhances the response of AML cells to several chemical treatments [46]-[50], including cytarabine [51]; therefore, we hypothesize that inhibiting CCN1 increases the cytarabine-induced apoptosis of AML cells by down-regulating the MEK/ERK signaling pathway.